TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30964819
Drug: Anti-Saccharomyces cerevisiae
Normalized name: Anti-Saccharomyces cerevisiae IgA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Saccharomyces cerevisiae mannan antibodies (ASCA)
Study: 30964819
Drug: Antineutrophil cytoplasmic
Normalized name: c-Antineutrophil cytoplasmic antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antineutrophil cytoplasmic antibodies
Study: 30965011
Drug: Double-Dose Alpha-1
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-Dose Alpha-1 Antitrypsin Augmentation Therapy
Study: 30968255
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training combined with chemotherapy
Study: 30968301
Drug: Antiplatelet agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet agent cangrelor
Study: 30968368
Drug: Lopinavir/Ritonavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/Ritonavir monotherapy
Study: 30968368
Drug: Combination antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiretroviral therapy (cART) with efavirenz/emtricitabine/tenofovir
Study: 30969486
Drug: Intensive lifestyle
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive lifestyle intervention programme with whey supplements (30 g/day) and personalized resistance training regimen for 32 elderly subjects from the sarcopenic cohort.
Study: 30969486
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of TNF-α (>11.15 pg/mL) and TWEAK (>1276.48 pg/mL) in sarcopenic patients.
Study: 30969486
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of serum levels of proinflammatory cytokines and metabolic hormones between sarcopenic and non-sarcopenic subjects.
Study: 30971261
Drug: EQ-5D-5 L
Normalized name: Anthelcide EQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: EQ-5D-5 L
Study: 30972619
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment (n=919)
Study: 30973373
Drug: Alisertib 20
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib 20 mg twice daily and Pazopanib 600 mg daily (DL 2)
Study: 30975203
Drug: Iron status
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron status assessment using plasma ferritin and soluble transferrin receptor (sTfR) measurements.
Study: 30975630
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m²), fluorouracil, and vincristine, administered in two 21-day cycles within 42 days of resection.
Study: 30975630
Drug: Cisplatin, fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin, fluorouracil, and vincristine (adjuvant chemotherapy).
Study: 30976780
Drug: Inflammation defined
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inflammation defined as CRP >5 mg/L or AGP >1 g/L, or both
Study: 30976898
Drug: Goal-directed fluid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed fluid therapy using esophageal Doppler monitoring (EDM) during laparoscopic adrenalectomy for PCC patients.
Study: 30976898
Drug: PCC patients
Normalized name: PCC
DrugBank: Factor IX Complex (Human) (DB11330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCC patients receiving goal-directed fluid therapy using EDM.
Study: 30978536
Drug: Bismuth salts
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth salts (240 mg) combined with proton pump inhibitors (esomeprazole, omeprazole, pantoprazole, rabeprazole), amoxicillin (1 g), and clarithromycin (500 mg), all taken twice daily for 14 days.
Study: 30978536
Drug: Bismuth salts
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth salts (240 mg) combined with standard triple therapy.
Study: 30978536
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy without bismuth (not explicitly mentioned in the abstract).
Study: 30978536
Drug: Bismuth salts
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth salts with a double dose of proton pump inhibitor (equivalent to 40 mg omeprazole).
Study: 30978536
Drug: 14-day duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day duration of treatment.
Study: 30978536
Drug: Treatment compliance.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment compliance.
Study: 30979361
Drug: Proposed treatment
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed treatment plan [multiple choice]
Study: 30979811
Drug: Low birth
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low birth weight (LBW) (<2500 g)
Study: 30980576
Drug: ombitasvir/paritaprevir/ritonavir +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ombitasvir/paritaprevir/ritonavir + dasabuvir with low-dose ribavirin for 12 weeks
Study: 30980734
Drug: Fostemsavir (FTR)
Normalized name: fostemsavir
DrugBank: Fostemsavir (DB11796)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostemsavir (FTR) 600 mg twice daily
Study: 30980827
Drug: Etonogestrel contraceptive
Normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etonogestrel contraceptive implants
Study: 30981783
Drug: Lentiviral vector-derived
Normalized name: Autologous CD34+ cells transduced with lentiviral vector which encodes for the aryl Sulfatase A complimentary deoxyribonucleic acid sequence
DrugBank: Atidarsagene autotemcel (DB17538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentiviral vector-derived gene therapy
Study: 30981987
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ctDNA, patient age, and serum biomarkers
Study: 31253622
Drug: Rectal screening
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal screening
Study: 30982000
Drug: Rectal site
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal site testing
Study: 30982564
Drug: Intraoperative low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraoperative low-dose fentanyl (about 60-120 μg for a 70 kg patient)
Study: 30982564
Drug: High intraoperative
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intraoperative fentanyl doses (median: 3.85; IQR: 3.42-4.50 μg kg)
Study: 30984354
Drug: Daily walnut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily walnut intake (45 g for 16 weeks)
Study: 30985279
Drug: Inhaled iloprost
Normalized name: iloprost Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled iloprost treatment via the Breelib nebulizer for 3 months ± 2 weeks, in addition to existing PAH therapy.
Study: 30985279
Drug: Inhaled iloprost
Normalized name: iloprost Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled iloprost treatment via the Breelib nebulizer.
Study: 30985369
Drug: Autologous fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous fat transfer (AFT); average volume: 23.9 ± 13.2 mL
Study: 30986523
Drug: Inappropriate empirical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate empirical antibiotic therapy (IEAT)
Study: 30986523
Drug: Inappropriate empirical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate empirical antibiotic therapy (IEAT) in bloodstream infections
Study: 30986735
Drug: Mood stabilizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mood stabilizing anticonvulsants (MSAs)
Study: 30986735
Drug: Polypharmacy (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (combination of drugs)
Study: 30986750
Drug: Moderate doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate doses of statins at discharge
Study: 30987597
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml albumin 5% administered over 1 min in three consecutive 50-ml fluid boluses, followed by an additional 350 ml infused at a constant rate over 15 min (total 500 ml)
Study: 30988080
Drug: High-dose lapatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose lapatinib (1,500 mg BID)
Study: 30988080
Drug: Intermittent high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent high-dose lapatinib alternating with capecitabine
Study: 30989436
Drug: Various anti-glioblastoma
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various anti-glioblastoma agents including temozolomide, carmustine, lomustine, procarbazine, irinotecan, cediranib, erlotinib, 5-fluorouracil, vincristine, dichloroacetate, IDH1 inhibitor ivosidenib; treatment duration: 3 or 6 days
Study: 30990523
Drug: 10% IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% IV infusion of glucose during exercise
Study: 30991823
Drug: Adaptive Cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive Cardiac Resynchronization Therapy
Study: 30991992
Drug: Micafungin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (50 mg intravenously once daily during first induction chemotherapy)
Study: 30994466
Drug: Dignity Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dignity Therapy (DT) led by nurses or chaplains
Study: 30994825
Drug: Dual anti-platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual anti-platelet therapy (DAPT)
Study: 30995146
Drug: Anti-clot treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-clot treatment scale
Study: 30995146
Drug: Treatment satisfaction
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment satisfaction questionnaire for medication version II
Study: 30995208
Drug: Vancomycin 15
Normalized name: vancomycin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 15 mg·kg infused over 1 hour, repeated every 12 hours
Study: 30995208
Drug: Cefazolin 30
Normalized name: cefazolin 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 30 mg·kg infused over 10 minutes, repeated every 4 hours
Study: 30995372
Drug: Lentiviral vector
Normalized name: Lentiviral Vector Expressing Human Fumarylacetoacetate Hydrolase
DrugBank: LV-FAH (DB17686)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentiviral vector gene therapy combined with low-dose busulfan conditioning
Study: 30995373
Drug: UB-421 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: UB-421 (10 mg/kg weekly)
Study: 30995373
Drug: UB-421 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: UB-421 (25 mg/kg every 2 weeks)
Study: 30996012
Drug: Selinexor 60
Normalized name: selinexor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor 60 mg orally twice weekly on days 1 and 3 of each week, three of each 4-week cycle
Study: 30997507
Drug: Low Energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Energy Density (LED) preload (33 kcal/100 g)
Study: 30997507
Drug: High Energy
Normalized name: High energy formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Energy Density (HED) preload (97.9 kcal/100 g)
Study: 30999933
Drug: Baricitinib 2
Normalized name: baricitinib 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 2 mg or 4 mg with or without concomitant methotrexate (MTX)
Study: 31003789
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein intake (≥1.3 g of protein/kg)
Study: 31003789
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake (<1.3 g of protein/kg)
Study: 31003963
Drug: Emicizumab 6
Normalized name: EMICIZUMAB 60 mg in 0.4 mL SUBCUTANEOUS INJECTION, SOLUTION [Hemlibra]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emicizumab 6 mg/kg subcutaneously every 4 weeks for 24 weeks or more (with 4 loading doses of 3 mg/kg once weekly for the expansion cohort)
Study: 31003963
Drug: Emicizumab 6
Normalized name: EMICIZUMAB 60 mg in 0.4 mL SUBCUTANEOUS INJECTION, SOLUTION [Hemlibra]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emicizumab 6 mg/kg subcutaneously every 4 weeks
Study: 31004324
Drug: Sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 200 mg SC every 2 weeks + methotrexate
Study: 31004598
Drug: Endoscopic eradication
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopic eradication therapy (EET) with complete eradication of intestinal metaplasia (CE-IM)
Study: 31005932
Drug: ICP monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ICP monitoring and ICP-driven therapy
Study: 31006811
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (25 g/d)
Study: 31006980
Drug: HCV direct-acting
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV direct-acting antiviral (DAA) treatment
Study: 31006980
Drug: Opioid substitutive
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid substitutive therapy (OST-PWID)
Study: 31006980
Drug: Recent people
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recent people who inject drugs (recent PWID)
Study: 31008307
Drug: Systems medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systems medicine approach to investigate complex risk-factor interactions
Study: 31008354
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of medication compliance
Study: 31009356
Drug: Intravenous tPA
Normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tPA therapy (IVT)
Study: 31009701
Drug: 5-grass tablet
Normalized name: Buffalo grass
DrugBank: Anthoxanthum odoratum (DB14163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-grass tablet (sublingual immunotherapy), daily dosage with a 3-day dose escalation to 300 index of reactivity (IR) for 30 days
Study: 31010300
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of daily living disability
Study: 31010434
Drug: Ad5-GUCY2C-PADRE vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5-GUCY2C-PADRE vaccine
Study: 31011205
Drug: WINTHER therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: WINTHER therapy
Study: 31011207
Drug: CD19-BBz(86) CAR
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19-BBz(86) CAR T cell therapy, dose: 2 × 10^6 cells
Study: 31011363
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 15 metabolites
Study: 31011363
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 15 metabolites and motilin
Study: 31012962
Drug: CC-486 300
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 300 mg daily on days 1 through 14 and romidepsin 8 mg/m²
Study: 31012967
Drug: Imatinib with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib with standard-dose induction and consolidation therapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) when possible.
Study: 31012967
Drug: Rescue chemotherapy
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue chemotherapy and TKI change followed by second allo-HSCT for overt disease recurrence.
Study: 31013390
Drug: CAM2038 weekly
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAM2038 weekly (8, 16, 24 or 32 mg) or monthly (64, 96, 128 or 160 mg)
Study: 31013390
Drug: CAM2038 weekly
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAM2038 weekly or monthly
Study: 31014072
Drug: Firibastat (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firibastat (250 mg BID for 2 weeks, then 500 mg BID if AOBP >140/90 mm Hg; hydrochlorothiazide 25 mg QD added after 1 month if AOBP ≥160/110 mm Hg)
Study: 31015389
Drug: Intravenous triiodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous triiodothyronine (0.4 μg/kg bolus followed by 0.6 μg/kg continuous perfusion for 24 h)
Study: 31016030
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) using a treat and extend (TAE) dosing regimen.
Study: 31016233
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy in the NBRST study (NCT01479101) for ER-positive HER2-negative breast cancers.
Study: 31018069
Drug: Tagraxofusp at
Normalized name: Tagraxofusp
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tagraxofusp at a dose of 12 μg per kilogram
Study: 31018069
Drug: Tagraxofusp at
Normalized name: Tagraxofusp
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tagraxofusp at a dose of 7 μg per kilogram
Study: 31018069
Drug: Tagraxofusp (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tagraxofusp (both doses)
Study: 31019106
Drug: Nusinersen (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nusinersen (12 mg, single-dose level)
Study: 31023296
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy administered by injection every 4 weeks
Study: 31024845
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose to reconstructed breast
Study: 31024845
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no radiation dose specified)
Study: 31024978
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with HEV239 vaccine
Study: 31027916
Drug: Abivertinib (50-350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abivertinib (50-350 mg twice daily or 300 mg twice daily)
Study: 31028053
Drug: Family-administered FAM-CAM
Normalized name: fam-trastuzumab deruxtecan-nxki
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Family-administered FAM-CAM
Study: 31028053
Drug: Family-administered Sour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-administered Sour Seven questionnaire
Study: 31028495
Drug: EXAcerbations of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: EXAcerbations of COPD Tool (EXACT®) questionnaire, daily observations over a year.
Study: 31028664
Drug: Ivosidenib 500
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivosidenib 500 mg QD
Study: 31028664
Drug: Ivosidenib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivosidenib (various doses from 100 mg BID to 1200 mg QD)
Study: 31028664
Drug: Ivosidenib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivosidenib (various doses)
Study: 31030414
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg bid for 4 days, followed by apixaban 10 mg and clarithromycin 500 mg bid on day 8.
Study: 31030414
Drug: Apixaban 10
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 10 mg alone on day 1 and day 8.
Study: 31031265
Drug: High-dose opioids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose opioids (increased dose over the last 14 days)
Study: 31031265
Drug: High-dose opioids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose opioids (no increase of dose over the last 14 days)
Study: 31032113
Drug: Trypan blue
Normalized name: Trypan Blue
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trypan blue capsule staining during phacoemulsification
Study: 31032113
Drug: Phacoemulsification without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phacoemulsification without trypan blue capsule staining (control)
Study: 31033034
Drug: Dimethylfumarate monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethylfumarate monotherapy
Study: 31033194
Drug: Anticoagulants stopped
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants stopped if d-dimer was negative
Study: 31033194
Drug: Anticoagulants continued
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants continued if d-dimer was positive
Study: 31033623
Drug: Isotope-labeled 3
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotope-labeled 3 mg aqueous zinc administered in the fasted state
Study: 31034595
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with breast cancer receiving chemotherapy
Study: 31035291
Drug: Mavacamten 10
Normalized name: mavacamten 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavacamten 10 to 20 mg/d (cohort A)
Study: 31035291
Drug: Mavacamten 2
Normalized name: mavacamten 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavacamten 2 to 5 mg/d with β-blockers (cohort B)
Study: 31036012
Drug: Non-biologic disease-modifying
Normalized name: cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-biologic disease-modifying antirheumatic drugs (non-bDMARDs)
Study: 31036012
Drug: Biologic disease-modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic disease-modifying antirheumatic drugs (biologic DMARDs)
Study: 31036770
Drug: Regorafenib 100
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 100 mg p.o. daily (continuous dosing)